Target Price | $10.33 |
Price | $1.28 |
Potential |
707.29%
register free of charge
|
Number of Estimates | 6 |
6 Analysts have issued a price target Regulus Therapeutics Inc. 2026 .
The average Regulus Therapeutics Inc. target price is $10.33.
This is
707.29%
register free of charge
$28.00
2,087.50%
register free of charge
$3.00
134.38%
register free of charge
|
|
A rating was issued by 6 analysts: 5 Analysts recommend Regulus Therapeutics Inc. to buy, 1 to hold and 0 to sell. | |
Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis. | |
Analyst Estimates: Analysts believe that the Regulus Therapeutics Inc. stock has an average upside potential 2026 of
707.29%
register free of charge
|
Dec '23 |
2024 Estimates |
|
---|---|---|
Earnings Per Share $ | -1.58 | -0.85 |
15.05% | 46.20% | |
P/E | negative |
6 Analysts have issued a Regulus Therapeutics Inc. forecast for earnings per share. The average Regulus Therapeutics Inc. <a href=https://blog.stocksguide.com/knowledge/eps-simply-explained>EPS is
This results in the following potential growth metrics and future valuations:
Regulus Therapeutics Inc....
Analyst | Rating | Action | Date |
---|---|---|---|
HC Wainwright & Co. | Locked ➜ Locked | Locked | Feb 26 2025 |
HC Wainwright & Co. | Locked ➜ Locked | Locked | Nov 11 2024 |
HC Wainwright & Co. | Locked ➜ Locked | Locked | Oct 30 2024 |
HC Wainwright & Co. | Locked ➜ Locked | Locked | Oct 08 2024 |
Analyst Rating | Date |
---|---|
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Feb 26 2025 |
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Nov 11 2024 |
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Oct 30 2024 |
Locked
HC Wainwright & Co.: Locked ➜ Locked
|
Oct 08 2024 |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.